Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity
Magdalena Eilenberg, Petra Munda, Judith Stift, Felix B Langer, Gerhard Prager, Michael Trauner, Katharina Staufer, Magdalena Eilenberg, Petra Munda, Judith Stift, Felix B Langer, Gerhard Prager, Michael Trauner, Katharina Staufer
Abstract
Background: Vibration controlled transient elastography (VCTE) and controlled attenuation parameter (CAP™) have shown reliable performance predicting fibrosis and steatosis in normal- to overweight patients but have not been validated in severe to morbid obesity. This study aimed at determining the accuracy of VCTE, CAP™ and the composite score FibroScan-AST (FAST) in patients with a body mass index (BMI) of ≥35 kg/m2.
Methods: Patients scheduled for bariatric-metabolic surgery underwent preoperative VCTE/CAP™ measurement, and intraoperative liver biopsy. The feasibility and accuracy of VCTE, CAP™ and the composite score FAST were retrospectively analysed to evaluate fibrosis, steatosis and active fibrotic non-alcoholic steatohepatitis [NASH + non-alcoholic fatty liver disease (NAFLD) activity score ≥4 + fibrosis grade ≥2] using per protocol (PP) and intent to diagnose (ITD) calculation.
Results: In total, 170 patients (median BMI 44.4 kg/m2) were included in the study. Liver biopsy showed NASH, simple steatosis, and normal livers in 60.6% (n=103), 28.8% (n=49), and 10.6% (n=18), respectively. VCTE and CAP™ delivered reliable results in 90.6% (n=154/170) and 90.5% (n=134/148). The AUC (PP) of VCTE, CAP™, and FAST were 0.687 (≥F2), 0.786 (≥F3), 0.703 (≥S2), 0.738 (S3), and 0.780 (active fibrotic NASH). The AUC increased to 0.742 (≥F2), 0.842 (≥F3), 0.712 (≥S2), 0.780 (S3), and 0.836 (active fibrotic NASH) in patients below the median BMI of 44.4 kg/m2.
Conclusions: VCTE, CAP™ and FAST show acceptable accuracy for the detection of fibrosis, steatosis and NASH in a real-life cohort of patients with obesity. Accuracy improves in patients with a BMI <44.4 kg/m2.
Keywords: FibroScan-AST score (FAST score); Transient elastography; controlled attenuation parameter (CAP™); non-alcoholic fatty liver disease (NAFLD); obesity.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/hbsn-20-787). Dr. MT reports personal fees from BMS, grants and personal fees from Falk Foundation, grants, personal fees and other from Gilead, grants, personal fees and other from Intercept, grants and personal fees from MSD, personal fees from Albireo, personal fees from Boehringer lngelheim, personal fees from BiomX, personal fees from Genfit, personal fees from Novartis, personal fees from Phenex, personal fees from Regulus, other from Abbvie, grants from Albireo, grants from Cymabay, grants from Takeda, outside the submitted work. In addition, Dr. MT has a patent Medical use of nor-UDCA (W02006119803 and W020099013334) licensed to Medical University of Graz. Dr. KS serves as an unpaid editorial board member of Hepatobiliary Surgery and Nutrition. The other authors have no conflicts of interest to declare.
2021 Hepatobiliary Surgery and Nutrition. All rights reserved.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8527403/bin/hbsn-10-05-610-f1.jpg)
Figure 2
Diagnostic accuracy of VCTE, CAP™…
Figure 2
Diagnostic accuracy of VCTE, CAP™ and FAST according to per protocol and intent…
Figure 3
Per protocol liver stiffness measurement…
Figure 3
Per protocol liver stiffness measurement (LSM) and CAP™ distribution stratified for fibrosis, steatosis,…
- Non-invasive tests for fibrosis detection: still in search for the best way.Ridola L, Capoccia D, Guarisco G, Riggio O, Leonetti F. Ridola L, et al. Hepatobiliary Surg Nutr. 2022 Dec;11(6):920-923. doi: 10.21037/hbsn-22-466. Hepatobiliary Surg Nutr. 2022. PMID: 36523934 Free PMC article. No abstract available.
- Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.Garteiser P, Castera L, Coupaye M, Doblas S, Calabrese D, Dioguardi Burgio M, Ledoux S, Bedossa P, Esposito-Farèse M, Msika S, Van Beers BE, Jouët P. Garteiser P, et al. JHEP Rep. 2021 Sep 30;3(6):100381. doi: 10.1016/j.jhepr.2021.100381. eCollection 2021 Dec. JHEP Rep. 2021. PMID: 34786549 Free PMC article.
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN. Eddowes PJ, et al. Gastroenterology. 2019 May;156(6):1717-1730. doi: 10.1053/j.gastro.2019.01.042. Epub 2019 Jan 25. Gastroenterology. 2019. PMID: 30689971
- Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.Loong TC, Wei JL, Leung JC, Wong GL, Shu SS, Chim AM, Chan AW, Choi PC, Tse YK, Chan HL, Wong VW. Loong TC, et al. J Gastroenterol Hepatol. 2017 Jul;32(7):1363-1369. doi: 10.1111/jgh.13671. J Gastroenterol Hepatol. 2017. PMID: 27936280
- Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Brandman D, Doo E, Tonascia JA, Kleiner DE, Chalasani N, Sanyal AJ; NASH Clinical Research Network. Siddiqui MS, et al. Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2. doi: 10.1016/j.cgh.2018.04.043. Epub 2018 Apr 26. Clin Gastroenterol Hepatol. 2019. PMID: 29705261 Free PMC article.
- Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.Cao YT, Xiang LL, Qi F, Zhang YJ, Chen Y, Zhou XQ. Cao YT, et al. EClinicalMedicine. 2022 Jul 10;51:101547. doi: 10.1016/j.eclinm.2022.101547. eCollection 2022 Sep. EClinicalMedicine. 2022. PMID: 35844772 Free PMC article.
- The Effects of Eight Weeks' Very Low-Calorie Ketogenic Diet (VLCKD) on Liver Health in Subjects Affected by Overweight and Obesity.Rinaldi R, De Nucci S, Castellana F, Di Chito M, Giannuzzi V, Shahini E, Zupo R, Lampignano L, Piazzolla G, Triggiani V, Cozzolongo R, Giannelli G, De Pergola G. Rinaldi R, et al. Nutrients. 2023 Feb 6;15(4):825. doi: 10.3390/nu15040825. Nutrients. 2023. PMID: 36839183 Free PMC article.
- Citrus Bergamia and Cynara Cardunculus Reduce Serum Uric Acid in Individuals with Non-Alcoholic Fatty Liver Disease.Ferro Y, Maurotti S, Mazza E, Pujia R, Sciacqua A, Musolino V, Mollace V, Pujia A, Montalcini T. Ferro Y, et al. Medicina (Kaunas). 2022 Nov 26;58(12):1728. doi: 10.3390/medicina58121728. Medicina (Kaunas). 2022. PMID: 36556930 Free PMC article. Clinical Trial.
- Non-invasive tests for fibrosis detection: still in search for the best way.Ridola L, Capoccia D, Guarisco G, Riggio O, Leonetti F. Ridola L, et al. Hepatobiliary Surg Nutr. 2022 Dec;11(6):920-923. doi: 10.21037/hbsn-22-466. Hepatobiliary Surg Nutr. 2022. PMID: 36523934 Free PMC article. No abstract available.
- Obesity-Induced Hepatic Steatosis Is Partly Mediated by Visceral Fat Accumulation in Subjects with Overweight/Obesity: A Cross-Sectional Study.Liu F, Chen S, Li X, Li S, Xiao Y, Han J, Tu Y, Bao Y, Bai W, Yu H. Liu F, et al. Obes Facts. 2023;16(2):164-172. doi: 10.1159/000527595. Epub 2022 Oct 18. Obes Facts. 2023. PMID: 36257286 Free PMC article.
- Associations between serum biomarkers and non-alcoholic liver disease: Results of a clinical study of Mediterranean patients with obesity.De Nucci S, Castellana F, Zupo R, Lampignano L, Di Chito M, Rinaldi R, Giannuzzi V, Cozzolongo R, Piazzolla G, Giannelli G, Sardone R, De Pergola G. De Nucci S, et al. Front Nutr. 2022 Sep 8;9:1002669. doi: 10.3389/fnut.2022.1002669. eCollection 2022. Front Nutr. 2022. PMID: 36159489 Free PMC article.
- Full Text Sources
- Medical
- Miscellaneous
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8527403/bin/hbsn-10-05-610-f2.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8527403/bin/hbsn-10-05-610-f3.jpg)
Source: PubMed